Acumen Pharmaceuticals, Inc. SEC filings ABOS
Acumen Pharmaceuticals, Inc. has 365 filings in SEC EDGAR's recent list, going back to May 15, 2013. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 26, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (agreement ended, exit or restructuring costs). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Agreement ended, Exit or restructuring costs
|
Nov 5, 2026 | Nov 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 16, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 26, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Mar 16, 2026 | Mar 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 10, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 15, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2024 | Jun 4, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2024 | Mar 26, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 19, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 1, 2024 | Feb 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2024 | Jan 12, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 4, 2023 | Dec 4, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 13, 2023 | Nov 13, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 13, 2023 | Nov 13, 2023 |
| 8-K |
Current report
Material agreement
|
Nov 9, 2023 | Nov 5, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 20, 2023 | Jul 18, 2023 |
| 8-K |
Current report
Results of operations
|
Jul 17, 2023 | Jul 17, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 17, 2023 | Jul 16, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 8, 2023 | Jun 6, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 27, 2023 | Apr 27, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 27, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 15, 2023 | Mar 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 1, 2023 | Feb 1, 2023 |
| 8-K |
Current report
Officer or director change
|
Jan 4, 2023 | Jan 3, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 14, 2022 | Nov 14, 2022 |
| 8-K |
Current report
Other events
|
Oct 24, 2022 | Oct 24, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 12, 2022 | Sep 12, 2022 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 15, 2022 | Aug 12, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 1, 2022 | Aug 1, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Results of operations
|
May 16, 2022 | May 16, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2022 | Mar 28, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 3, 2022 | Jan 1, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 15, 2021 | Nov 15, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 7, 2021 | Oct 7, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 31, 2021 | Aug 31, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 16, 2021 | Aug 16, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jul 7, 2021 | Jul 6, 2021 |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ABOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newton, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1576885
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.